Prediction of portal vein thrombosis after splenectomy and its primary prophylaxis with antithrombin III concentrates in liver cirrhosis with portal hypertension

Prediction of portal vein thrombosis after splenectomy and its primary prophylaxis with antithrombin III concentrates in liver cirrhosis with portal hypertension - Risk level of PVT after splenectomy and prophylaxis with AT-III

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013134

Enrollment

100

Registered

2014-02-12

Start date

2008-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cirrhotic patients who underwent laparoscopic splenectomy

Interventions

intravenous infusion of 1,500 units of AT-III concentrates (Anthrobin P&amp

reg

CSL Behring, Tokyo, Japan) over approximately 1 hour on postoperative day 1, 2, and 3 intravenous administration of AT-III concentrates (1500 units/day) for three days followed by intravenous admini

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cirrhotic patients who underwent laparoscopic splenectomy

Exclusion criteria

Exclusion criteria: 1. Patients who had portal vein thrombosis before the operation 2. Patients who had postoperative bleeding requiring hemostasis

Design outcomes

Primary

Measure	Time frame
To classify risk level of portal vein thrombosis (PVT) after splenectomy in cirrhotic patients	—

Secondary

Measure	Time frame
To develop prophylactic treatments of PVT according to the risk level of PVT after splenectomy in cirrhotic patients	—

Countries

Japan

Contacts

Public ContactHirofumi Kawanaka

Fukuoka City Hospital Department of Surgery

harrykw@v102.vaio.ne.jp092-632-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026